Walleye Trading
TVTX icon

Walleye Trading’s Travere Therapeutics TVTX Stock Holding History

Walleye Trading’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,900
Closed -$378K – 4740
2025
Q4 		$378K Sell
9,900
-14,100
-59% -$458K ﹤0.01% 3003
2025
Q3 		$574K Buy
+24,000
New +$451K ﹤0.01% 2648
2022
Q1 		– Sell
-500
Closed -$16K – 5930
2021
Q4 		$16K Buy
+500
New +$14.1K ﹤0.01% 4995
2021
Q1 		– Sell
-5,900
Closed -$161K – 5314
2020
Q4 		$161K Buy
+5,900
New +$138K ﹤0.01% 3664
2020
Q3 		– Sell
-9,300
Closed -$190K – 4635
2020
Q2 		$190K Buy
+9,300
New +$148K ﹤0.01% 3107
2019
Q4 		– Sell
-24,000
Closed -$278K – 4648
2019
Q3 		$278K Buy
+24,000
New +$397K ﹤0.01% 2657
2019
Q1 		– Sell
-7,800
Closed -$177K – 4785
2018
Q4 		$177K Sell
7,800
-27,400
-78% -$682K ﹤0.01% 3497
2018
Q3 		$1.01M Buy
+35,200
New +$1.01M 0.01% 2053
2018
Q1 		– Sell
-22,400
Closed -$470 – 4813
2017
Q4 		$470 Buy
+22,400
New +$512K ﹤0.01% 2663

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Trading's TVTX Position: Q1 2026 in Review

Walleye Trading sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 374 shares — an estimated $14.3K sold.

Walleye Trading first reported a position in TVTX in Q2 2015 and held it in 17 quarters. The position peaked at $785K in Q3 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Walleye Trading reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 374 Travere Therapeutics shares in Q1 2026, an estimated $14.3K.
  • Walleye Trading first reported a position in Travere Therapeutics in Q2 2015 and held it in 17 quarters.
  • Walleye Trading's Travere Therapeutics position peaked at $785K in Q3 2022.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.